Improvements in the field of liver transplantation;Fortschritte auf dem gebiet der lebertransplantation

Chirurgische Gastroenterologie Interdisziplinar

Volumn 20, Issue SUPPL. 1, 2004, Pages 28-35

  Pfitzmann, R ^a   Neuhaus, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Extracorporeal liver support; Immunosuppression; Liver transplantation; Living donor related liver transplantation; Xenotransplantation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; FAMCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

CONTROLLED STUDY; GERMANY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; ORGAN DONOR; PERFORMANCE; POSTOPERATIVE COMPLICATION; REVIEW; SURGICAL TECHNIQUE;

EID: 4644349471     PISSN: 01779990     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080535     Document Type: Review

References (53)

1. Consensus conference on indications of liver transplantation. Hepatology 1984;4(suppl 1):63S-68S.
2. Neuhaus P, Pfitzmann R (Hrsg): Aktuelle Aspekte der Lebertransplantation. Bremen, UNI-MED, 2003.
3. Deutsche Stiftung Organtransplantation: www.dso.de.
4. The US Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1117.
5. European FK506 Multicentre Liver Study Group: Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994;344:423-427.
6. Neuhaus P, Blumhardt G, Bechstein WO, Platz KP, Jonas S, Mueller AR, Langrehr JM, Lohmann R, Schattenfroh N, Knoop M, Keck H, Lemmeni P, Raakow R, Lüsebrink R, Slama KJ, Lobeck H, Hopf U: Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation 1995;59:31-40.
7. Neuhaus P, Platz KP, Mueller AR: Liver transplantation - technical complications; in O'Grady JG, Lake JR, Howdle PD (eds): Comprehensive Clinical Hepatology, Section 4. London, Mosby, 2000, pp 38.1-38.14.
8. European Liver Transplant Registry Study: Normalised intrinsic mortality risk in liver transplantation: Lancet 2000;356:621-627.
9. Berg T, Bechstein WO, Müller AR, Neuhaus P, Hopf U: Lebertransplantation. Internist 1998;39:1237-1245.
10. Carithers RL Jr: Liver transplantation. Liver Transpl 2000;6:122-135.
11. Tillmann HL, Manns MP: Indikationen zur Lebertransplantation. Dtsch Med Wochenschr 2003;128(suppl 2):S104-S106.
12. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, for the EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. J Hepatol 2001;35:421-430.
13. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086.
14. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
15. Pascher A, Jonas S, Neuhaus P: Intrahepatic cholangiocarcinoma: Indication for transplantation. J Hepatobiliary Pancreat Surg 2003;10:282-287.
16. Pfitzmann R, Heise M, Steinmüller T, Raakow R, Settmacher U, Neuhaus P: Transplantationschirurgie (Teil III). Zentralbl Chir 2001;126:W25-34.
17. Neuhaus P, Blumhardt G, Bechstein WO, Steffen R, Platz KP, Keck H: Technique and results of biliary reconstruction using side-to-side choledochocholedochostomy in 300 orthotopic liver transplants. Ann Surg 1994;219:426-434.
18. Bechstein WO, Neuhaus P: Bleeding problems in liver surgery and liver transplantation. Chirurg 2000;71:363-368.
19. Hintze RE, Abou-Rebyeh H, Adler A, Veltzke W, Langrehr J, Wiedenmann B, Neuhaus P: Therapie ischämietypischer biliärer Läsionen (ITBL) bei Patienten nach orthoper Lebertransplantation. Z Gastroenterol 1999;37:13-20.
20. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B, for the CHIC 304 International Liver Study Group: Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142.
21. Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, Hopf U, Radke C, Neuhaus P: Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant Proc 1998;30:2232-2233.
22. Mita MM, Mita A, Rowinsky EK: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003;2(suppl 1):S169-177.
23. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2000;120:1828-1853.
24. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O: Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: Long-term results. Am J Transplant 2003;3:999-1002.
25. Seehofer D, Rayes N, Steinmüller T, Müller AR, Settmacher U, Neuhaus R, Radke C, Berg T, Hopf U, Neuhaus P: Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001;7:976-982.
26. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM: Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001;34:411-416.
27. Seehofer D, Rayes N, Naumann U, Neuhaus R, Müller AR, Tullius SG, Berg T, Steinmüller T, Bechstein WO, Neuhaus P: Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001;72:1381-1385.
28. Manns MP, Neuhaus P, Atkinson GF, Griffin KE, Barnass S, Vollmar J, Yeang Y, Young CL, for the Famciclovir Liver Transplant Study Group: Famciclovir treatment of hepatitis B infection following liver transplantation: A long-term, multi-center study. Transpl Infect Dis 2001;3:16-23.
29. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
30. Beckebaum S, Cicinnati VR, Gerken G, Broelsch CE: Treatment of hepatitis B reinfection after liver transplantation. Minerva Chir 2003;58:705-716.
31. McHutchison JG: Hepatitis C advances in antiviral therapy: What is accepted treatment now? J Gastroenterol Hepatol 2002;17:431-441.
32. Dusheiko G, Main J, Thomas J, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O: Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-598.
33. Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, Baratti D, Romano F, Palazzo U, Zuin M, Bonino F, Ribero ML, Gennari L: Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-521.
34. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492
35. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR: Combination of interferon and ribavirin in chronic hepatitis C: Retreatment of nonresponders to interferon. Hepatology 2001;33:704-707.
36. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351-1358.
37. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
38. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, for the Hepatitis Interventional Therapy Group: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2a as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
39. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2a for initial treatment of chronic hepatitis C. Lancet 2001;358:958-965.
40. Féray C, Caccamo L, Alexander GJM: European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
41. Broelsch CE, Frilling A, Nadalin S, Valentin GC, Kuhl H, Gerken G, Malago M: Leberlebendspende. Die deutsche Erfahrung im internationalen Vergleich. Chirurg 2003;74:510-522. Erratum in Chirurg 2003;74:1039.
42. Broelsch CE, Malagó M, Testa G, Gamazo CV: Living donor liver transplantation in adults: outcome in Europe. Liver Transpl 2000;6(suppl 2):S64-S65.
43. Trotter JF: Selection of donors and recipients for living donor liver transplantation. Liver Transpl 2000;6(suppl 2):S52-S56.
44. Settmacher U, Neuhaus P: Innovation in der Leberchirurgie durch die Transplantation mit Lebendspende. Chirurg 2003;74:536-546.
45. Settmacher U, Steinmüller T, Luck W, Eisele R, Thernvath T, Heise M, Neuhaus P: Complex vascular reconstruction in living donor liver transplantation. Transplant Int 2003;16:742-747.
46. Puhl G: Extrakorporale Leberunterstützungsverfahren; in Neuhaus P, Pfitzmann R (Hrsg): Aktuelle Aspekte der Lebertransplantation. Bremen, UNI-MED, 2003, pp 58-65.
47. Gerlach JC, Encke J, Hole O, Müller C, Ryan CJ, Neuhaus P: Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation 1994;58:984-988.
48. Gerlach J, Ziemer R, Neuhaus P: Fulminant liver failure: Relevance of extracorporeal hybrid liver support systems. Int J Artif Organs 1996;19:7-13.
49. Gerlach J: Development of a hybrid liver support system: A review. Int J Artif Organs 1996;19:645-654.
50. Sauer IM, Zeilinger K, Pless G, Kardassis D, Theruvath T, Pascher A, Goetz M, Neuhaus P, Gerlach JC: Extracorporeal liver support based on primary human liver cells and albumin dialysis - treatment of a patient with primary graft nonfunction. J Hepatol 2003;39:649-653.
51. Pascher A. Xenotransplantation; in Neuhaus P, Pfitzmann R (Hrsg): Aktuelle Aspekte der Lebertransplantation. Bremen, UNI-MED, 2003, pp 68-70.
52. Pascher A, Sauer I.M., Hammer C, Gerlach JC, Neuhaus P: Extracorporeal liver perfusion as hepatic assist in acute liver failure: A review of world experience. Xenotransplantation 2002;9:309-324.
53. Michaels MG, Jenkins FJ, St.George K, Nalesnik MA, Starzl TE, Rinaldo CR Jr: Detection of infectious baboon cytomegalovirus after baboonto-human liver xenotransplantation. J Virol 2001;75:2825-2828.